**Core Concept**
Nesiritide is a recombinant human B-type natriuretic peptide (BNP) analogue used in the management of acute decompensated heart failure. It acts by promoting vasodilation, reducing cardiac preload, and decreasing systemic vascular resistance.

**Why the Correct Answer is Right**
Nesiritide works by binding to natriuretic peptide receptors on vascular smooth muscle cells, leading to the activation of guanylyl cyclase and an increase in cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP levels cause smooth muscle relaxation, resulting in vasodilation and decreased systemic vascular resistance. This effect reduces the workload on the heart, thereby improving cardiac output and reducing symptoms of heart failure.

**Why Each Wrong Option is Incorrect**
**Option A:**
This statement might be true, but without text it is difficult to assess its correctness. However, based on the properties of nesiritide, it is plausible that this statement is indeed true.

**Option B:**
This statement is likely incorrect. Nesiritide is known to have a neutral effect on cardiac contractility and does not have a significant inotropic effect.

**Option C:**
This statement is likely incorrect. Nesiritide is a vasodilator and does not have a significant effect on cardiac contractility or afterload.

**Option D:**
This statement is likely incorrect. Nesiritide is used in the management of acute decompensated heart failure, but its use is not limited to this condition.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that nesiritide should be used cautiously in patients with renal impairment, as it may worsen renal function due to its vasodilatory effects.

**Correct Answer: B. Nesiritide is a vasodilator and does not have a significant effect on cardiac contractility or afterload.**